prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Temporary Copy. Diagnosis. A. SENTINEL LYMPH NODE, EXCISION: - ONE LYMPH NODE WITH REACTIVE SINUS HISTIOCYTOSIS. - NEGATIVE FOR CARCINOMA (0/1). B. RIGHT BREAST, TRUE MEDIAL MARGIN, EXCISION: - BENIGN BREAST TISSUE WITH USUAL DUCTAL HYPERPLASIA. - NEGATIVE FOR CARCINOMA. C. RIGHT BREAST, LUMPECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 2, 2.2 CM. - DUCTAL CARCINOMA IN SITU, GRADE 2, CRIBIFORM TYPE WITH CENTRAL NECROSIS. (Electronic signature). Verified: Synoptic Report. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 2.2 cm. Additional dimensions: 1.9 X 1.0 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Skin is not present. Skeletal Muscle: No skeletal muscle present. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. SIZE (EXTENT) OF DCIS: Number of blocks with DCIS: 3. Number of blocks examined: 7. ARCHITECTURAL PATTERNS: Cribriform (with central necrosis). NUCLEAR GRADE: Grade II (intermediate). NECROSIS: Present, central (expansive "comedo" necrosis). LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in. both size and shape. MITOTIC COUNT: Temporary Copy. TD: Score 1. Number of mitoses per 10 high-power fields: 3. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 2: scores of 6 or 7. MARGINS: Margins uninvolved by invasive carcinoma. Distance from superior margin: 8.0 mm. Distance from inferior margin: 12.0 mm. Distance from anterior margin: 6.0 mm. Distance from posterior margin: 5.0 mm. Distance from medial margin: 5.0 mm (at least 5mm. Measurment obtained from specimen B). Distance from lateral margin: 14.0 mm. Margins uninvolved by DCIS (if present). Distance from closest margin: 12.0 mm. Distance from inferior margin: 12.0 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Not identified. DERMAL LYMPH-VASCULAR INVASION: No skin present. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Number of lymph nodes with macrometastases (>0,2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: H&E, multiple levels. Immunohistochemistry. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pNO: No regional lymph node metastasis identified histologically. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: Intraductal papillomas. ESTROGEN RECEPTOR: Performed on another specimen. Specimen (accession number): Immunoreactive tumor cells present (greater than or equal to 1%). Quantitation: 100%. PROGESTERONE RECEPTOR: Performed on another specimen. Specimen (accession number): Immunoreactive turnor cells present (greater than or equal to 1%). Quantitation: 65%. Temporary Copy. lo. HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on another specimen. Specimen (accession number): Equivocal (Score 2+). FLUORESCENCE IN SITU HYBRIDIZATION (FISH) FOR HER2/NEU: Performed on another specimen. Specimen (accession number): Not amplified (HER2 gene copy <4.0 or ratio <1.8). MICROCALCIFICATIONS: Not identified. COMMENT(S): Largest focus of residual tumor in lumpectomy identified was 1.2 x 0.9 cm. Largest biopsy dimension. was 1.1 cm. Therefore gross measurement including cavity is accurate for staging purposes. Specimen Source. A. Sentinel node. Clinical Information. Right breast carcinoma. Gross Description. A. the specimen is received fresh in her grouping agreed with the patient's name and "sentinel lymph node". It. consists of segment of fibroadipose tissue harboring a blue tinged lymph node which measures 2.0 x 1.3 x 0.9. cm in greatest dimension. Bisected and submitted entirely in 2 cassettes Al and A2. B. the specimen is received fresh in a container labeled with the patient's name and "right breast and medial. margin". It consists of a segment of ligament and fibroadipose tissue measuring 4 x 2 x 0.5 cm. Two long. stitches indicates the medial margin, a long single stitch indicates the superior margin. The specimen is serially. sectioned from superior to inferior and submitted entirely in 3 cassettes. Section key: B1 superior. B2 B3 inferior. C. the specimen is received fresh in a container labeled with the patient's name and "right breast tissue". It. consists of a segment of lobulated adipose tissue measuring 4.5 x 3 x 2.5 cm, double long stitch indicates 12:00,. a single long stitch indicates 6:00, double short stitch indicates the deep margin. There is an irregularly-shaped white brown mass that measures 2.2 x 1.9 x 1 cm with a central cavity and. numerous calcifications. This mass is very close to the medial margin (no specific color, see slide key), it is at. 0.9 cm from the inferior, 0.8 cm from superior, 1.4 cm from the lateral, 0.8 cm from anterior, 1.0 cm from. posterior. The remaining of the tissue is lobulated adipose tissue. Ink key: Inferior green, anterior red, superior orange, posterior back, lateral yellow, inferior green. The speciment is representatively submitted as follows: C1-C2 mass-medial margin. C3 lateral margin. C4 anterior margin. C5 posterior margin. C6 superior margin. C7 inferior margin. Surgical Pathology Finat Report. Temporary Copy. Pattent. DE. Specimen removed from patient at. Specimen sectioned and mass fixed in formalin at. for at least 6 hours and less than 48 hours. Cold ischemic time: 15 minutes. Special Stains / Slides. Immunohistochemical studies for AEI/AE3 were performed on formalin fixed, paraffin-embedded tissue (Block. A1-2) with adequate positive and negative control sections. The stains are negative, supporting the above. diagnosis. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food and. Drug Administration The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They. should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement. Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. 14he, 2ihc. Tissue Code.

expanded version (tokens=2254) : 
 Histological classification: 
- Invasive ductal carcinoma (no special type or not otherwise specified) 
- Ductal carcinoma in situ, grade 2, cribriform type with central necrosis

Subtype: LumA

Necrosis: Present, central (expansive "comedo" necrosis) in DCIS

Tumor infiltrating lymphocytes: Not identified

Histological grade: Grade 2 (intermediate)

Nuclear grade: Grade II (intermediate)

Lymphovascular invasion: Not identified

Calcification: Numerous calcifications present

Receptor status: 
- Estrogen receptor: Immunoreactive tumor cells present (greater than or equal to 1%). Quantitation: 100%. 
- Progesterone receptor: Immunoreactive tumor cells present (greater than or equal to 1%). Quantitation: 65%. 
- HER2/NEU: Equivocal (Score 2+). Fluorescence in situ hybridization (FISH) performed and not amplified (HER2 gene copy <4.0 or ratio <1.8).

IHC and ancillary testing results: 
- Immunohistochemical studies for AEI/AE3 were performed and the stains were negative 
- No treatment effect due to presurgical therapy was identified
- No lymph node metastasis identified histologically

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2420) : 
 LumA subtype invasive ductal carcinoma with central necrosis in DCIS. Grade 2 nuclear histological grade and equivocal HER2/NEU status. No lymphovascular invasion or tumor infiltrating lymphocytes identified. Estrogen and progesterone receptor-positive (quantitation: 100% and 65%, respectively). No presurgical therapy/treatment effect noted but no lymph node metastasis identified histologically. No special stains or ancillary testing performed except for negative AEI/AE3 immunohistochemical stains on formalin-fixed, paraffin-embedded tissue.

